Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“In that study, patients were randomized either to that regimen or to sunitinib (a VEGF inhibitor); significant prolongation of PFS and overall survival was observed, with 42% of patients achieving a response (many of these durable)11,12.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [11]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Diarrhea 145 (27) 21 (4) 278 (52) 28 (5)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 4×
“Female 111 (26) 121 (29) 137 (25) 151 (28)”
InfluentialTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1)”
Cited by
Items 501–600 of 1,016
Mori, K., Abufaraj, M. M., Mostafaei, H., Quhal, F., Fajković, H., Remzi, M., Karakiewicz, P. I., Egawa, S., Schmidinger, M., Shariat, S. F., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.10.006 · Cited by 75
Agostinetto, E., Eiger, D., Lambertini, M., Ceppi, M., Bruzzone, M., Ponde, N. F., Plummer, C., Awada, A. H., Santoro, A., Piccart, M. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.043 · Cited by 70
Moran, M., Nickens, D. J., Adcock, K., Bennetts, M., Desscan, A., Charnley, N., & Fife, K. M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00653-5 · Cited by 78
Singla, N., Elias, R. M., Ghandour, R. A., Freifeld, Y. N., Bowman, I. A., Rapoport, L. M., Enikeev, M. E., Lohrey, J., Woldu, S. L., Gahan, J. C., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.08.012 · Cited by 67
Self-citationThe Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age
Huang, J. J., & Hsieh, J. J.-D. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.12.004 · Cited by 71
Mou, H., Yu, L., Liao, Q., Hou, X., Wu, Y., Cui, Q., Yan, N., Ma, R., Wang, L., Yao, M., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5021-2 · Cited by 67
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma
de Velasco, G., Bex, A., Albiges, L. K., Powles, T. B., Rini, B. I., Motzer, R. J., Heng, D. Y. C., & Escudier, B. J. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.06.022 · Cited by 69
Self-citationKao, H., & Lou, P. (2019) · Head & Neck · doi:10.1002/hed.25930 · Cited by 70
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 68
LncRNA SNHG3, a potential oncogene in human cancers
Xu, B., Mei, J., Ji, W., Bian, Z., Jiao, J., Sun, J., & Shao, J. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01608-x · Cited by 71
Msaouel, P., Goswami, S., Thall, P. F., Wang, X., Yuan, Y., Jonasch, E. W., Gao, J., Campbell, M. T., Shah, A. Y., Corn, P. G., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm6420 · Cited by 68
Self-citationPal, S. K., Miller, M. J., Agarwal, N., Chang, S. M., Chávez‐MacGregor, M., Cohen, E. E. W., Cole, S., Dale, W., Diefenbach, C., Disis, M. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02037 · Cited by 77
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 80
Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 78
Navani, V., & Heng, D. Y. C. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4337 · Cited by 71
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
Whelan, R., Prince, E. W., Gilani, A., & Hankinson, T. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020519 · Cited by 65
Argentiero, A., Solimando, A. G., Krebs, M., Leone, P., Susca, N., Brunetti, O., Racanelli, V., Vacca, A., & Silvestris, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051594 · Cited by 64
“The treatment scenario of mRCC has largely evolved in the last years, translating into an outcome improvement achieved by targeting VEGF/VEGFR pathways (bevacizumab, sorafenib, sunitinib, pazopanib, axitinib, cabozantinib and lenvatinib) [86–92], mTOR signaling (everolimus and temsirolimus) [93,94] and immunocheckpoin…”
BackgroundDeferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma
Bhindi, B., Graham, J., Wells, J. C., Bakouny, Z., Donskov, F. N., Fraccon, A. P., Pasini, F., Lee, J., Basappa, N. S., Hansen, A. R., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.038 · Cited by 63
Self-citationPowell, N., Ibraheim, H., Raine, T., Speight, A., Papa, S., Brain, O., Green, M., Samaan, M., Spain, L. A., Yousaf, N., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30014-5 · Cited by 67
Dizman, N., Lyou, Y., Salgia, N., Bergerot, P. G., Hsu, J., Enriquez, D., Izatt, T., Trent, J. M., Byron, S. A., & Pal, S. K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000953 · Cited by 68
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786046 · Cited by 76
“(25) Nivolumab + ipilimumab vs sunitinib Total – 847 OS (among intermediate and high-risk pts) <65 - 524 0.”
BackgroundTargeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance
Deng, J., Zhou, M. L., Liao, T., Kuang, W., Xia, H., Yin, Z., Tan, Q., Li, Y., Song, S., Zhou, E., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818453 · Cited by 68
Carril-Ajuria, L., Desnoyer, A., Meylan, M., Dalban, C., Naigeon, M., Cassard, L., Vano, Y. A., Rioux-Leclercq, N. C., Chouaïb, S., Beuselinck, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004885 · Cited by 69
Self-citationIpilimumab in combination with nivolumab for the treatment of renal cell carcinoma
Gao, X. Y., & McDermott, D. F. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1513485 · Cited by 67
“Nivolumab + Ipilimumab (CheckMate 214) [15] Sunitinib (CheckMate 214) [15] Cabozantinib (CABOSUN) [59] Sunitinib (CABOSUN) [59]”
BackgroundMethodResultInfluentialSelf-citationMøller, N. B., Budolfsen, C., Grimm, D. G., Krüger, M., Infanger, M., Wehland, M., & Magnusson, N. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194712 · Cited by 74
“It was demonstrated that this risk model could distinguish patients with mRCC into two groups that benefitted most from either immune checkpoint blockade versus sunitinib [74].”
BackgroundTargeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease
Kemeny, H. R., Elsamadicy, A. A., Farber, S. H., Champion, C. D., Lorrey, S., Chongsathidkiet, P., Woroniecka, K. I., Cui, X., Shen, S. H., Rhodin, K. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3486 · Cited by 66
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer
Chang, A. E., Golob, J. L., Schmidt, T. M., Peltier, D. C., Lao, C. D., & Tewari, M. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.02.005 · Cited by 62
Paderi, A., Giorgione, R., Giommoni, E., Mela, M., Rossi, V., Doni, L., Minervini, A., Carini, M., Pillozzi, S., & Antonuzzo, L. (2021) · Cancers · doi:10.3390/cancers13040860 · Cited by 62
D’Aniello, C., Berretta, M., Cavaliere, C., Rossetti, S., Facchini, B. A., Iovane, G., Mollo, G., Capasso, M., Pepa, C. D., Pesce, L., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01400 · Cited by 68
“Recently the Checkmate 214 showed the efficacy of Ipilimumab plus Nivolumab inmccRCC, across all risk groups, although VEGFRi (sunitinib) performed better in good IMDC risk groups, due to the higher angiogenesis expression signatures, typical of this group (107).”
BackgroundLu, C. C., Li, X. N., Broglio, K. R., Bycott, P. W., Jiang, Q., Li, X., McGlothlin, A. E., Tian, H., & Ye, J. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00315-7 · Cited by 73
Oza, B., Frangou, E., Smith, B., Bryant, H., Kaplan, R. S., Choodari‐Oskooei, B., Powles, T., Stewart, G. D., Albiges, L. K., Bex, A., et al. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106482 · Cited by 71
Self-citationIntestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Zhou, Y., Medik, Y. B., Patel, B., Zamler, D. B., Chen, S., Chapman, T., Schneider, S., Park, E. M., Babcock, R. L., Chrisikos, T. T., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20221333 · Cited by 62
“…checkpoint mechanisms has provided the most significant breakthrough in cancer treatment in the past decade with demonstrated clinical success in controlling a variety of aggressive tumors (Curran et al., 2010; Hellmann et al., 2018; Hodi et al., 2018; Leach et al., 1996; Motzer et al., 2018).”
Shah, N. J., Sura, S. D., Shinde, R., Shi, J., Singhal, P. K., Robert, N. J., Vogelzang, N. J., Perini, R. F., & Motzer, R. J. (2023) · European Urology Open Science · doi:10.1016/j.euros.2022.12.015 · Cited by 64
Self-citationNivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Vos, J. L., Burman, B., Jain, S., Fitzgerald, C. W. R., Sherman, E. J., Dunn, L. A., Fetten, J. V., Michel, L. S., Kriplani, A., Ng, K., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02518-x · Cited by 68
“Resistant tumors showed upregulation of inhibitory MDSCs and M2 TAMs or other T cell checkpoints, possibly posing targetable adaptive resistance mechanisms 12,61 .”
Kanesvaran, R., Saux, O. L., Motzer, R. J., Choueiri, T. K., Scotté, F., Bellmunt, J., & Launay‐Vacher, V. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30125-6 · Cited by 67
Self-citationDeveloping combination strategies using PD-1 checkpoint inhibitors to treat cancer
Schmidt, E. V. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-018-0714-9 · Cited by 61
Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
Regan, M. M., Jegede, O. A., Mantia, C. M., Powles, T. B., Werner, L. L., Motzer, R. J., Tannir, N. M., Lee, C., Tomita, Y., Voss, M. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2283 · Cited by 67
“8) intermediate or poor prognostic risk (9).”
BackgroundInfluentialSelf-citationHosein, A. N., Dangol, G., Okumura, T., Roszik, J., Rajapakshe, K., Siemann, M., Zaid, M., Ghosh, B., Monberg, M., Guerrero, P. A., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.273 · Cited by 61
Nunno, V. D., Mollica, V., Gatto, L., Santoni, M., Cosmai, L., Porta, C., & Massari, F. (2019) · Immunotherapy · doi:10.2217/imt-2018-0175 · Cited by 61
Self-citationCancer immunotherapy: the art of targeting the tumor immune microenvironment
da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 67
Xu, J., Hu, Z., Cao, H., Zhang, H., Luo, P., Zhang, J., Wang, X., Cheng, Q., & Li, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.981764 · Cited by 85
Larcher, A., Wallis, C. J. D., Bex, A., Blute, M. L., Ficarra, V., Méjean, A., Karam, J. A., Poppel, H. V., & Pal, S. K. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.04.007 · Cited by 66
Donskov, F. N., Xie, W., Overby, A., Wells, J. C., Fraccon, A. P., Sacco, C. S. P., Porta, C., Stukalin, I., Lee, J., Koutsoukos, K., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.01.001 · Cited by 61
“Motzer et al [14] 2007 Sunitinib Interferon-a Yes (not per arm) MSKCC No AVOREN [15] 2007 Bevacizumab + interferon-a Interferon-a Yes MSKCC MSKCC Global ARCC [16] 2007 Temsirolimus Interferon-a Yes MSKCC No CALGB 90206 [17] 2008 Bevacizumab + interferon-a Interferon-a No MSKCC MSKCC Sternberg et al [18] 2010 Pazopanib…”
BackgroundSelf-citationZhan, L., Feng, H.-F., Liu, H., Guo, L., Chen, C., Yao, X.-L., & Sun, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649863 · Cited by 65
PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies
Mucileanu, A., Chira, R. I., & Mircea, P. A. (2021) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2116 · Cited by 61
Emamekhoo, H., Olsen, M. R., Carthon, B. C., Drakaki, A., Percent, I. J., Molina, A. M., Cho, D. C., Bendell, J. C., Gordan, L., Kalebasty, A. R., et al. (2021) · Cancer · doi:10.1002/cncr.34016 · Cited by 63
“The long- term efficacy and tolerability of NIVO + IPI for patients with previously untreated aRCC demonstrated in CM214 was based on outcomes in patients who had aRCC and a predominantly clear cell component.(12,18) Data evaluating NIVO + IPI in patients with aRCC and brain metastases are limited, although antitumor…”
MethodResultGlioma and the gut–brain axis: opportunities and future perspectives
Dono, A., Nickles, J., Rodriguez-Armendariz, A. G., McFarland, B. C., Ajami, N. J., Ballester, L. Y., Wargo, J. A., & Esquenazi, Y. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac054 · Cited by 68
Capdevila, J., Hernando, J., Teulé, À., López, C., García‐Carbonero, R., Benavent, M., Custodio, A., García‐Álvarez, A., Cubillo, A., Alonso, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38611-5 · Cited by 64
“Immunecheckpointinhibition(ICI)ofprogrammeddeathligand1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) has changed the paradigm in many cancer types 15,16 .”
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 81
Kinget, L., Naulaerts, S., Govaerts, J., Vanmeerbeek, I., Sprooten, J., Laureano, R. S., Dubroja, N., Shankar, G., Bosisio, F. M., Roussel, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02978-9 · Cited by 69
Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 69
“Compared to sunitinib, the incidence of disease progression or death was signi fi cantly reduced (HR 0.63, p 0.001), although the improvement in PFS did not meet the prespeci fi ed threshold for statistical signi fi cance (HR 0.82, p=0.03) (82).”
InfluentialPembrolizumab for the treatment of cervical cancer
Marret, G., Borcoman, É., & Tourneau, C. L. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1646721 · Cited by 62
Errarte, P., Larrinaga, G., & Lopez, J. I. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2019.09.004 · Cited by 71
“demonstrated in a study with more than 1000 patients that overall survival and response rate were significantly higher in patients with nivolumab/ipilimumab treatment than with sunitinib [33].”
Roelants, C., Pillet, C., Franquet, Q., Sarrazin, C., Peilleron, N., Giacosa, S., Guyon, L., Fontanell, A., Fiard, G., Long, J., et al. (2020) · Cancers · doi:10.3390/cancers12010232 · Cited by 71
“In agreement with the key role played by the immune infiltrate in ccRCC, a phase 3 clinical trial (CheckMate214) showed benefits in terms of overall survival and objective response rate using an immunotherapy combination (ipilinumab plus nivolumab) versus sunitinib for intermediate and poor-risk patients with previous…”
BackgroundHarrison, M. R., Costello, B. A., Bhavsar, N. A., Vaishampayan, U. N., Pal, S. K., Zakharia, Y., Jim, H., Fishman, M., Molina, A. M., Kyriakopoulos, C. E., et al. (2021) · Cancer · doi:10.1002/cncr.33494 · Cited by 66
Self-citationFormate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade
Rowe, J. H., Elia, I., Shahid, O., Gaudiano, E. F., Sifnugel, N. E., Johnson, S., Reynolds, A. G., Fung, M. E., Joshi, S., LaFleur, M. W., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1301 · Cited by 59
Mori, K., Mostafaei, H., Miura, N., Karakiewicz, P. I., Luzzago, S., Schmidinger, M., Bruchbacher, A., Pradère, B., Egawa, S., & Shariat, S. F. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02684-8 · Cited by 63
Dong, Y., Wong, J. S. L., Sugimura, R., Lam, K. O., Li, B. K., Kwok, G. W., Leung, R. C.-Y., Chiu, J. W. Y., Cheung, T. T., & Yau, T. C. C. (2021) · Cancers · doi:10.3390/cancers13081949 · Cited by 65
Atallah, E., Welsh, S. J., O’Carrigan, B., Oshaughnessy, A., Dolapo, I., Kerr, A. S., Kucharczak, J., Lee, C. Y. C., Crooks, C. J., Hicks, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100851 · Cited by 70
Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy—A Systematic Review
Pierrard, J., & Seront, E. (2019) · Current Oncology · doi:10.3747/co.26.5177 · Cited by 64
Flaifel, A., Xie, W., Braun, D. A., Ficial, M., Bakouny, Z., Nassar, A. H., Jennings, R. B., Escudier, B. J., George, D. J., Motzer, R. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1135 · Cited by 61
“On the other hand, in the frontline CheckMate-214 trial (Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma), patients with PD-L1 expression in TC were more likely to derive clinical benefit from the combination of nivolumab (anti–PD-1) and ipilimuma…”
BackgroundResultSelf-citationPetrelli, F., Stefani, A. D., Trevisan, F., Parati, M. C., Inno, A., Merelli, B., Ghidini, M., Bruschieri, L., Vitali, E., Cabiddu, M., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102830 · Cited by 59
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
Isaacs, J. M., Anders, C. K., McArthur, H. L., & Force, J. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00833-4 · Cited by 64
Mahé, I., Agnelli, G., Ay, C., Bamias, A., Becattini, C., Carrier, M., Chapelle, C., Cohen, A. T., Girard, P., Huisman, M. V., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1647-9896 · Cited by 62
Kovacs, S., & Győrffy, B. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03409-4 · Cited by 67
“The ipilimumab plus nivolumab combination was also approved for advanced renal cell carcinoma [11], microsatellite instability-high/mismatch repairdeficient (MSI-H/dMMR) metastatic colorectal carcinoma [12], hepatocellular carcinoma [13], and metastatic non-small cell lung cancer (NSCLC) in case the tumor cells expres…”
BackgroundImmune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
Hu, Z. I., Link, V. M., Lima-Junior, D. S., Delaleu, J., Bouladoux, N. J., Han, S., Collins, N., & Belkaid, Y. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200348119 · Cited by 61
Haanen, J. B. A. G., Larkin, J., Choueiri, T. K., Albiges, L. K., Rini, B. I., Atkins, M. B., Schmidinger, M., Penkov, K., Michelon, E., Wang, J., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101210 · Cited by 65
“In other phase III trials evaluating 1L treatment for patients with aRCC, OS and PFS benefits have been seen across IMDC risk groups for combinations of an immune checkpoint inhibitor with a VEGFR inhibitor,(13-15) whereas in an exploratory analysis from the phase III CheckMate 214 trial of nivolumab plus ipilimumab v…”
BackgroundSelf-citationContemporary treatment of metastatic renal cell carcinoma
Wiechno, P., Kucharz, J., Sadowska, M., Michalski, W., Sikora-Kupis, B., Jońska‐Gmyrek, J., Poniatowska, G., Nietupski, K., Ossoliński, K., & Demkow, T. (2018) · Medical Oncology · doi:10.1007/s12032-018-1217-1 · Cited by 66
Overview of current and future systemic therapy for metastatic renal cell carcinoma
Osawa, T., Takeuchi, A., Kojima, T., Shinohara, N., Eto, M., & Nishiyama, H. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz013 · Cited by 69
Subudhi, S. K., Siddiqui, B. A., Aparicio, A. M., Yadav, S. S., Basu, S., Chen, H., Jindal, S., Tidwell, R. S. S., Varma, A., Logothetis, C. J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002919 · Cited by 67
Self-citationPal, K., Madamsetty, V. S., Dutta, S. K., & Mukhopadhyay, D. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s204221 · Cited by 58
“Recently, Food and Drug Administration and the European Medicines Agency approved the combination of two immune checkpoint inhibitors, nivolumab and ipilimumab, as the new standard of care treatment for intermediate- and poor-risk patients, as the combination demonstrated better efficacy than sunitinib.(25) In additio…”
BackgroundDufies, M., Grytsai, O., Ronco, C., Oumar, C., Ambrosetti, D., Hagege, A., Parola, J., Mateo, L., Ayrault, M., Giuliano, S., et al. (2019) · Theranostics · doi:10.7150/thno.34681 · Cited by 57
“Indeed, immunotherapy improved the outcome of RCC [35, 40] and HNSCC [41].”
Immunotherapy approaches for malignant pleural mesothelioma
Fennell, D. A., Dulloo, S., & Harber, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00649-7 · Cited by 65
Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment
Birnboim-Perach, R., & Benhar, I. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.93697 · Cited by 62
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 61
Nie, R., Chen, F., Yuan, S., Luo, Y.-S., Chen, S., Chen, Y., Chen, X., Chen, Y.-B., Li, Y., & Zhou, Z. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.011 · Cited by 63
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options
Ahrens, M., Scheich, S., Hartmann, A., Bergmann, L., & IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society (2019) · Oncology Research and Treatment · doi:10.1159/000495366 · Cited by 57
The tumor microenvironment in renal cell cancer
Mier, J. W. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000512 · Cited by 66
Grimm, M., Bex, A., Santis, M. D., Ljungberg, B., Catto, J. W. F., Rouprêt, M., Hussain, S. A., Bellmunt, J., Powles, T., Wirth, M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.05.041 · Cited by 61
“PD-L1 status is also recorded in many ongoing ICI trials; the recently reported results from the JAVELIN Renal 101 trial [6] provide support that in advanced, clear-cell RCC, therapy outcomes aremore favorable in PD-L1-positive patients treated with avelumab plus axitinib.”
BackgroundResultInfluentialSelf-citationYang, Y., Jin, G., Pang, Y., Huang, Y., Wang, W., Zhang, H., Tuo, G., Wu, P., Wang, Z., & Zhu, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00040 · Cited by 57
Li, M., Sack, J. S., Rahma, O. E., Hodi, F. S., Zucker, S. D., & Grover, S. (2020) · Cancer · doi:10.1002/cncr.33165 · Cited by 55
“There is ample evidence that patients with metastatic melanoma have improved survival when treated with combined CTLA-4 and PD-1 inhibition versus single-agent anti–CTLA-4 therapy,(6-8) and combination therapy also has been shown to be beneficial in patients with renal cell carcinoma and hepatocellular carcinoma.(9,10…”
BackgroundImmunotherapy for Prostate Cancer
Venturini, N. J., & Drake, C. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030627 · Cited by 61
“Based on positive phase III data, the combination of anti-PD-1 and anti-CTLA-4 is agency approved in melanoma and kidney cancer (Motzer et al. 2018).”
BackgroundBerezhnoy, A., Sumrow, B. J., Stahl, K., Shah, K., Liu, D., Li, J., Hao, S.-S., De Costa, A., Kaul, S., Bendell, J., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100163 · Cited by 56
Vaishampayan, U. N., Schöffski, P., Ravaud, A., Borel, C., Peguero, J. A., Chaves, J. M., Morris, J. C., Kotecki, N., Šmakal, M., Zhou, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0746-2 · Cited by 58
“…studies of anti – PD-1/PD-L1 antibodies in combination with targeted therapies as 1 L treatment for advanced or metastatic RCC were reported [14, 24 – 27]; this includes trials of avelumab combined with axitinib, particularly the recently reported phase III JAVELIN Renal 101 study, which…”
BackgroundInfluentialSelf-citationImmunotherapy in older patients with cancer
Granier, C., Gey, A., Roncelin, S., Weiss, L., Paillaud, É., & Tartour, É. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.07.009 · Cited by 63
“[74] Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al.”
BackgroundIncorvaia, L., Fanale, D., Badalamenti, G., Brando, C., Bono, M., Luca, I. D., Algeri, L., Bonasera, A., Corsini, L. R., Scurria, S., et al. (2020) · Cancers · doi:10.3390/cancers12113396 · Cited by 58
Aeppli, S., Schmaus, M., Eisen, T., Escudier, B. J., Grünwald, V., Larkin, J., McDermott, D. F., Oldenburg, J., Porta, C., Rini, B. I., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100030 · Cited by 61
“In the CheckMate 214 trial, OS was significantly higher for the combination of ipilimumab and nivolumab compared to the standard treatment with sunitinib in intermediate- and poor-risk patients based on the International Metastatic renal cell carcinoma (RCC) Database (IMDC) risk classification.(7) Sunitinib was again…”
MethodSelf-citationMattila, K. E., Vainio, P., & Jaakkola, P. (2022) · Cancers · doi:10.3390/cancers14010239 · Cited by 74
“This feature renders sRCCs more susceptible to ICI than to antiangiogenic TKI therapies, and the introduction of ICI has significantly improved treatment outcomes in patients with advanced sRCC [90,92].”
BackgroundResultFaiella, A., Riccardi, F., Cartenì, G., Chiurazzi, M., & Onofrio, L. (2022) · Journal of Oncology · doi:10.1155/2022/5179182 · Cited by 63
“[119] to evaluate the combination of Nivolumab plus ipilimumab versus sunitinib, a well-known c-MET inhibitor, in the setting of advanced RCC.”
BackgroundLim, W., Kao, H., Suteja, L., Li, C. H., Quah, H. S., Tan, D. S. W., Tan, S. H., Tan, E.-H., Tan, W.-L., Lee, J. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38407-7 · Cited by 61
“Combination PD-1/CTLA-4 inhibition has proven effective in several tumor types, improving on responses to single-agent ICB-therapy, and is now standard of care in malignant melanoma 27 and renal cell carcinoma 28 .”
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 62
“(2018) [39] CheckMate 214 III Advanced, untreated disease A.”
BackgroundInfluentialTargeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
Aggen, D. H., Drake, C. G., & Rini, B. I. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3323 · Cited by 60
“In the context of kidney cancer, the PD-1– specific therapies nivolumab (2, 3) and pembrolizumab (4), as well as the PD-L1 antibody avelumab (5) are FDA-approved in combination with other therapies for metastatic renal cell carcinoma (RCC).”
BackgroundSelf-citationChoosing tumor mutational burden wisely for immunotherapy: A hard road to explore
Li, R., Han, D., Shi, J., Han, Y., Tan, P., Zhang, R., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188420 · Cited by 67
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Procopio, G., Apollonio, G., Cognetti, F., Miceli, R., Milella, M., Mosca, A., Chiurì, V. E., Bearz, A., Morelli, F., Ortega, C., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.08.011 · Cited by 58
Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma
Mantia, C. M., & McDermott, D. F. (2019) · Cancer · doi:10.1002/cncr.32361 · Cited by 59
“A significant benefit to treatment with combination therapy is a 9% CR rate with nivo/ipi and a 9% and 5% CR rate with atezolizumab plus bevacizumab in PD-L1–positive patients and an intention-to-treat population, respectively.(36,41) Although VEGF inhibitor and ICI combinations showed improved ORR and PFS compared wi…”
ResultSelf-citationMontemagno, C., Hagege, A., Borchiellini, D., Thamphya, B., Rastoin, O., Ambrosetti, D., Iovanna, J., Rioux-Leclercq, N. C., Porta, C., Négrier, S., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1846901 · Cited by 61
Self-citationChoueiri, T. K., Larkin, J., Pal, S. K., Motzer, R. J., Rini, B. I., Venugopal, B., Alekseev, B. Y., Miyake, H., Gravis, G., Bilen, M. A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100101 · Cited by 58
Self-citationTung, I., & Sahu, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.707214 · Cited by 57
“001), when compared to the control arm of sunitinib in those with intermediate or poor IMDC risk (15).”
Result
Metadata
- Authors
- Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., & Escudier, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) — both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center (D.F.M.), and Dana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman),...
- ORCID
- Motzer, Robert J.
- Tannir, Nizar M.
- McDermott, David F.
- Melichar, Bohuslav
- Choueiri, Toni K.
- Plimack, Elizabeth R.
- Barthélémy, Philippe
- Porta, Camillo
- George, Saby
- Powles, Thomas
- Donskov, Frede
- Kollmannsberger, Christian K.
- Salman, Pamela
- Gurney, Howard
- Ravaud, Alain
- Grimm, Marc-Oliver
- Barrios, Carlos H.
- Tomita, Yoshihiko
- Castellano, Daniel
- Rini, Brian I.
- Mekan, Sabeen
- McHenry, M. Brent
- Sharma, Padmanee
- Hammers, Hans J.
- Escudier, Bernard
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-05
- Volume
- 378
- Issue
- 14
- Pages
- 1277-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5972549
- OpenAlex
- W2792937256
- Cited by
- 4,656
- References
- 31
- Citations by year
- 2026: 305 · 2025: 416 · 2024: 510 · 2023: 601 · 2022: 656 · 2021: 708 · 2020: 684 · 2019: 562 · 2018: 209
- FWCI
- 408.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical Company Limited
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab plus ipilimumab, sunitinib, advanced renal cell carcinoma, clear cell renal cell carcinoma, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, combination immunotherapy, overall survival, objective response rate, progression-free survival, treatment-related adverse events, immune-related adverse events, first-line therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Sunitinib, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Quality of Life, Risk, Survival Rate, Survival Analysis, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.